Although platinum-based drugs, such as cisplatin, have achieved great success in cancer treatment and are presently enclosed in the majority of clinical protocols for the management of solid malignancies, their use are associated with significant drawbacks such as severe toxic effects on normal tissues and early appearance of drug resistance phenomena, calling for innovative metal-based drugs endowed with a better pharmacological profile.
We have developed a set of novel coper(I)-based compounds with anti-cancer properties. The choice of copper instead of platinum has several advantages, such as increased accumulation in cancer cells and reduced toxicity due to existence of natural biological pathways that regulate copper levels and detoxify the metal where necessary.
Our proprietary copper complexes show outstanding in vitro antitumor activity against a wide panel of human cancer cell lines, including platinum resistant and multidrug resistant cancer cells. In vivo, compounds induce a remarkable reduction of tumor growth while manifesting a minimal animal toxicity.

TRL

Lead Optimization/Preclinical

Inventors

Valentina
Gandin

Cristina
Marzano

Marina
Porchia

Francesco
Tisato

Download the brochure

  • Small molecule inhibitors of OPA1 GTPase activity with anti-cancer properties

    Cancer is a complex disease resulting from the interplay between the tumor cell and its microenvironment, featuring impaired apoptosis and activation of quiescent blood vessels to induce neovascularization to support metastasis. Two of the yet unmet needs in anticancer therapy[...]

  • Tioridazine analogues for acute myeloid leukemia treatment

    Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking. Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to[...]

  • SerpinB3 inhibitor for tumor treatment

    Expression of SerpinB3, a member of serine-protease inhibitor family, is associated with the carcinogenesis process as it determines resistance to apoptosis, induces cell proliferation and greater cell invasiveness. Furthermore, it leads to impaired immune surveillance and reduced chemosensitivity. Recent studies[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation